Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer – Final Appraisal Determination

In DRAFT guidance, NICE recommends atezolizumab with nab-paclitaxel for treating triple-negative, unresectable, locally advanced or metastatic breast cancer in adults whose tumours express PD-L1 at a level of ≥1% and who have not had previous chemotherapy for metastatic disease.

SPS commentary:

The positive recommendation follows consultation on NICE’s previous draft guidance which did not recommend atezolizumab. The company has agreed to provide a larger discount to the list price of the drug following a deal with NHS England & NHS Improvement. The use of atezolizumab is recommended only if the company provides it according to the commercial arrangement.


National Institute for Health and Care Excellence